Crinetics Pharmaceuticals CRNX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Crinetics Pharmaceuticals (CRNX) reported comprehensive income (loss), net of tax, attributable to parent of -$130.96M in Q1 2026.
- How has Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 36.8% year-over-year, from -$95.74M to -$130.96M.
- What is the long-term trend for Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 44.0% compound annual growth rate (CAGR), from -$108.05M to -$464.42M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This is the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It provides a comprehensive view of the company's total financial performance and changes in net worth beyond standard net earnings. It is a critical measure for assessing the overall economic impact of all financial activities on shareholder value.